Erythematous Lesion on the Nose

Spectrum of imiquimod‐induced lupus‐like reactions: Report of two cases

“…Imiquimod is a topical immunomodulator approved for treating superficial skin tumors, through activation of toll-like receptor (TLR). A few cases of imiquimod-induced cutaneous "lupus-like"reactions have been reported (Table 1) (Barr et al, 2010;Burnett et al, 2010;Chan & Zimarowski, 2011;Fernández et al, 2018;Jiménez-Gallo et al, 2017;Maguiness et al, 2015). We report two cases of imiquimod-induced lupus-like reactions, illustrating the spectrum of such reactions including the first case, to our knowledge, of imiquimod-induced systemic lupus erythematosus (SLE).…”

Lupus‐like reaction following imiquimod treatment for actinic keratoses

“…Imiquimod is a topical inmunomodulator with antiviral and antineoplastic properties widely used in dermatology. [1][2][3][4][5][6][7] Beyond the approved indications (treatment of actinic keratosis, superficial F I G U R E 1 Clinical presentation and histological findings. (A) A well-demarcated, infiltrated, erythematous plaque on the left cheek.…”

“…(B) A dense perivascular and periadnexal lymphoid infiltrate formed by lymphocytes without atypical features extending deep down to the vessels of the dermal-hypodermal junction (hematoxylin and eosin, original magnification 40Â). (C) A well-developed interface lesion with dyskeratotic keratinocytes predominantly affecting the follicular epithelium (hematoxylin and eosin, original magnification 100Â) 7), enhancing the immune system response. 1,2 Typical local adverse effects include erythema, burning, pain, crusting, and erosion.…”

“…Clinical picture included erythematous or scaly plaques located in photoexposed areas (facial region and trunk) developing weeks to months after imiquimod application. [1][2][3][4][5][6][7] The long interval from imiquimod treatment to lesions development is hard to explain and we have not found further information about this issue in the literature. Nevertheless, our case latency fits into the reported in previous cases.…”

“…Nevertheless, our case latency fits into the reported in previous cases. [1][2][3][4][5][6][7] Discontinuation of imiquimod and treatment with topical corticosteroids or hydroxychloroquine lead to resolution with no recurrence in most cases. [1][2][3][4][5][6][7] Autoantibody detection has shown variable results with four positive cases, two negative and three not reported.…”